Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan

Hematology (United States)

Volumn 21, Issue 1, 2016, Pages 3-9

  Chen, Yi Yang ^a   Huang, Cih En ^a   Lee, Kuan Der ^a,b   Chen, Chih Cheng ^a,b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Asian population; INC424; JAK2 mutation; MF SAF; Ruxolitinib; Splenomegaly

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEMOGLOBIN; JANUS KINASE 2; LACTATE DEHYDROGENASE; RUXOLITINIB; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE PAIN; CACHEXIA; CHRONIC HEPATITIS B; CLINICAL ARTICLE; COMPASSIONATE USE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTRANSAMINASEMIA; INTERMEDIATE RISK PATIENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; MALE; MYALGIA; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPHTHISIC ANEMIA; NAUSEA; NEUTROPENIA; POLYCYTHEMIA VERA; PRURITUS; QUALITY OF LIFE; RETROSPECTIVE STUDY; SATIETY; SIDE EFFECT; SPLEEN SIZE; SWEATING; TAIWAN; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY; VIRUS REACTIVATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; BONE MARROW; DRUG EFFECTS; ENZYMOLOGY; ETHNOLOGY; GENE EXPRESSION; GENETICS; MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLEEN; SPLENOMEGALY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; BONE MARROW; FEMALE; GENE EXPRESSION; HUMANS; JANUS KINASE 2; MALE; MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SPLEEN; SPLENOMEGALY; TAIWAN; TREATMENT OUTCOME;

EID: 85009956258     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1179/1607845415Y.0000000036     Document Type: Article

References (28)

1. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008;83(6):491-7.
2. Vannucchi AM. Management of myelofibrosis. Hematol Am Soc Hematol Educ Program. 2011;2011:222-30.
3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009 Mar; 113(13):2895-901.
4. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Res. 2009 Sep;33(9):1199-203.
5. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2): 127-40.
6. Cross NCP. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program. 2011;2011:208-14.
7. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118(7):1723-35.
8. Ward AC, Touw I, Yoshimura AA. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood [Internet]. 2000; 95(1):19-29PB-. Available from: http://www.bloodjournal.org/content/95/1/19.abstract.
9. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012; 19(26):4399-413.
10. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109-17.
11. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
12. Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98.
13. Cervantes F, Vannucchi AM, Kiladjian J-J, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122(25):4047-53.
14. Jung CW, Shih L-Y, Xiao Z, Jie J, Hou HA, Du X, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymph. 2015 Jul;56(7):2067-74.
15. Oritani K, Okamoto S, Tauchi T, Saito S, Ohishi K, Handa H, et al. A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis. Int J Hematol. 2015;101(3):295-304.
16. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of postpolycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22(2):437-8.
17. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115(9): 1703-8.
18. Shen C-H, Hwang C-E, Chen Y-Y, Chen C-C. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol. 2013; 93(6):1075-6.
19. Deisseroth A, Kaminskas E, Grillo J, ChenW, Saber H, Lu HL, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012 Jun;18(12):3212-7.
20. Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leuk Lymph. 2014 Jan; 55(1):195-7.
21. Tabarroki A, Visconte V, Rogers HJ, Sekeres MA, Samaras C, Lichtin A, et al. Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease. Leuk Lymph. 2014 Jan;55(1):213-6.
22. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120(6):1202-9.
23. Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28(1):225-7.
24. Tong LX, Jackson J, Kerstetter J, Worswick SD. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatology 2014 Mar;70(3):e59-e60.
25. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369(7): 681-3.
26. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013;122(23):3843-4.
27. Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014 Apr;123(14):2157-60.
28. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Journal of Hematology & Oncology. 2013 Oct;29(6):1-1.